CKD Fibrosis Drug Landscape 2025: A Complete Guide from Approved Therapies to Next-Generation Pipelines
A comprehensive overview of the CKD drug development landscape. From the 3 proven therapies (Finerenone, SGLT2i, GLP-1RA) to emerging Phase 2/3 pipelines—Aldosterone Synthase Inhibitors (ASIs), Endothelin Receptor Antagonists (ERAs), and Complement Pathway Inhibitors—with the latest clinical data and antifibrotic mechanisms.
1. A New Dawn for Renal Fibrosis and CKD Treatment
Chronic Kidney Disease (CKD) is a massive global public health challenge affecting approximately 800 million people. The ultimate common pathological pathway for CKD is Renal Fibrosis—progressive glomerulosclerosis and tubulointerstitial fibrosis that inevitably leads to End-Stage Kidney Disease (ESKD).
For decades, the standard of care (SoC) for CKD was largely limited to hemodynamic management using RAS inhibitors (ACEi or ARBs) to control blood pressure and reduce proteinuria. Drugs directly targeting the underlying "fibrosis" and "inflammation" were glaringly absent. However, the CKD treatment landscape is currently undergoing a dramatic paradigm shift.
This report comprehensively analyzes the recent clinical breakthroughs (including the FLOW and FINE-ONE trials) and the preclinical anti-inflammatory/antifibrotic mechanisms of the three therapeutic pillars redefining CKD treatment in 2024-2025: Finerenone (nsMRA), SGLT2 inhibitors, and GLP-1 receptor agonists. Furthermore, we cover the next-generation pipelines currently in Phase 2/3 clinical trials—Aldosterone Synthase Inhibitors (ASIs), Endothelin Receptor Antagonists (ERAs), and Complement Pathway Inhibitors.
1.1 Conventional Standard of Care (SoC) and Its Limitations
For decades, the bedrock of CKD pharmacotherapy has been RAS inhibitors (ACEi or ARBs). While they reduce intraglomerular pressure and proteinuria, they carry significant limitations:
- No direct action on fibrosis: Once collagen has been deposited (fibrosis) or chronic inflammation has set in, RAS inhibitors have limited disease-modifying capability to reverse or halt these processes.
- Incomplete protection: RAS inhibitors alone cannot fully arrest CKD progression in many patients, and a significant proportion still progress to ESKD.
It is precisely this unmet medical need that catalyzed the emergence of the three therapeutic pillars described below, as well as the next-generation pipeline compounds now advancing through clinical trials.
2. The Three Key Drivers of Antifibrotic Kidney Protection
These three drug classes are moving beyond "symptom management" into the realm of disease modification, actively slowing the structural deterioration (fibrosis) of the kidneys.
2.1 Finerenone: Non-steroidal Mineralocorticoid Receptor Antagonist (MRA)
- Brand: Kerendia (Bayer)
Overactivation of the Mineralocorticoid Receptor (MR) directly drives inflammation and fibrosis in the kidneys and heart. While older steroidal MRAs (like spironolactone) carried high risks of hyperkalemia and endocrine side effects, the non-steroidal Finerenone offers high MR selectivity with a significantly improved safety profile.
[Clinical Breakthrough: 2025 Developments] Finerenone is already approved to mitigate CKD progression in patients with Type 2 Diabetes (T2D) based on the FIDELIO-DKD1 and FIGARO-DKD2 trials. The paramount development in 2025 was the presentation of the Phase 3 FINE-ONE trial3 at ASN Kidney Week. In this trial, finerenone significantly reduced the urine albumin-to-creatinine ratio (UACR) in patients with CKD associated with Type 1 Diabetes (T1D)—a patient population that has seen almost no new therapeutic advancements in decades. Label expansions for T1D are anticipated in 2026.
[Preclinical Mechanism: Direct Antifibrotic Action] Finerenone exerts clear renal protection independent of blood pressure lowering. In preclinical models of renal fibrosis such as Unilateral Ureteral Obstruction (UUO), finerenone has been proven to profoundly suppress macrophage infiltration and block the production of pro-fibrotic cytokines (e.g., TGF-β), thereby directly preventing glomerular and interstitial collagen deposition.
[Safety Considerations] The primary adverse effect of finerenone is hyperkalemia, requiring regular serum K+ monitoring. Notably, when co-administered with SGLT2 inhibitors, the risk of hyperkalemia appears to be somewhat mitigated compared to finerenone monotherapy.
2.2 SGLT2 Inhibitors (SGLT2i)
- Examples: Dapagliflozin (Farxiga), Empagliflozin (Jardiance)
Originally introduced solely as glucose-lowering agents for T2D, SGLT2 inhibitors are now foundationally recommended as first-line therapy to slow CKD progression "irrespective of diabetes status" (KDIGO 2024 Guidelines), following the landmark successes of DAPA-CKD4 and EMPA-KIDNEY5.
[Preclinical Mechanism: The Metabolism-Fibrosis Link] The renoprotective mechanisms of SGLT2i are remarkably multifaceted:
- Lowering Intraglomerular Pressure: They restore tubuloglomerular feedback (TGF), correcting glomerular hyperfiltration and alleviating mechanical damage.
- Suppression of Pro-fibrotic Signaling: SGLT2i have been shown to directly inhibit the canonical TGF-β/Smad signaling pathway.
- Senotherapeutic Effects: Cutting-edge insights from 2024-2025 reveal that SGLT2i combat cellular senescence and oxidative stress in renal tubular cells, thereby halting the epithelial-to-mesenchymal transition (EMT) that drives fibroblast accumulation.
2.3 GLP-1 Receptor Agonists (GLP-1RA)
- Examples: Semaglutide (Ozempic/Wegovy)
Famous for dramatic weight-loss and potent glycemic control, GLP-1RAs are now demonstrating independent, profound renoprotective properties.
[Clinical Breakthrough: The FLOW Trial] In the landmark 2024 Phase 3 FLOW trial6, semaglutide (1.0 mg) significantly reduced the risk of major kidney outcomes (including progression to kidney failure or halving of eGFR) by 24% compared to placebo in CKD patients with T2D. This definitively established GLP-1RAs not just as metabolic agents, but as primary "renal therapeutics."
[Preclinical Mechanism: Masters of Anti-Inflammation] GLP-1 receptors are expressed on immune cells as well as in the kidney. GLP-1RAs powerfully reduce oxidative stress and inhibit major inflammatory cascades, including the NF-κB pathway. Because persistent local inflammation in the renal microenvironment is the primary trigger for fibrosis (collagen deposition), this robust anti-inflammatory action acts upstream to ultimately delay the progression of renal fibrosis.
Stay up to date with fibrosis research
Get notified when we publish new articles on preclinical models, drug pipelines, and assay protocols.
3. Next-Generation Pipeline Compounds (Phase 2/3)
While the three established pillars are consolidating their roles, a new wave of compounds with distinct mechanisms of action are advancing rapidly through clinical trials targeting renal fibrosis.
3.1 Aldosterone Synthase Inhibitors (ASIs)
Unlike Finerenone (which blocks the receptor), ASIs inhibit the production of aldosterone itself at the enzyme level. This approach minimizes off-target effects on cortisol signaling while effectively controlling MR overactivation.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Baxdrostat | AstraZeneca | Phase 3 | Large-scale Phase 3 trial with dapagliflozin in CKD + hypertension is ongoing8. Phase 2 showed UACR reduction |
| Lorundrostat | Mineralys Therapeutics | Phase 2 | Explore-CKD trial9: Achieved significant reductions in SBP and UACR in CKD + hypertension. NDA submission planned for 2025-2026 |
| Vicadrostat (BI 690517) | Boehringer Ingelheim | Phase 2→3 | Phase 2: UACR reduced by up to ~40% with empagliflozin10. Phase 3 EASi-KIDNEY trial (~11,000 patients, 15-20 countries) is underway |
3.2 Endothelin Receptor Antagonists (ERAs)
Endothelin-1 (ET-1) is a potent vasoconstrictor that also directly promotes mesangial cell proliferation and collagen deposition, driving renal fibrosis. ERAs block this pathway, but historically fluid retention was a limiting side effect. The current paradigm combines ERAs with SGLT2 inhibitors to offset this risk.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Atrasentan | Novartis | Phase 3 / Approved | ALIGN trial11 (IgA nephropathy): Confirmed eGFR decline slowing. Received US accelerated approval in 2025 |
| Sparsentan | Travere Therapeutics | Approved | Dual ET/AT1 antagonist. FDA full approval for IgA nephropathy (2024)12. Phase 3 DUPLEX trial for FSGS ongoing |
| Zibotentan + Dapagliflozin | AstraZeneca | Phase 3 | ZENITH-CKD (Phase 2b): Significant albuminuria reduction. Phase 3 ZENITH High Proteinuria trial13 is ongoing |
3.3 Complement Pathway Inhibitors
In diseases such as IgA nephropathy and C3 glomerulopathy, where aberrant immune activation drives fibrosis, complement cascade inhibition has proven effective. Multiple agents are now approved or nearing approval.
| Compound | Developer | Phase | Key Trial & Results |
|---|---|---|---|
| Iptacopan (Fabhalta) | Novartis | Phase 3 / Approved | Factor B inhibitor. APPLAUSE-IgAN trial14: Proteinuria reduced by 38%. Approved for C3G (2025) |
| Sibeprenlimab (Voyxact) | Otsuka / Visterra | Approved | Anti-APRIL antibody. Approved for IgA nephropathy (2025)15 |
4. The Future Standard: Layered Combination Therapy
The KDIGO 2024 Guidelines and the 2025 ADA Standards of Care now strongly advocate for a "Layered Therapeutic Strategy" incorporating all these agents:
- Foundation: RAS inhibitors (ACEi/ARB) for hemodynamic control.
- Layer 1: SGLT2 inhibitors to correct intraglomerular pressure and metabolic stress.
- Layer 2: GLP-1RAs (for robust inflammatory and weight control) or Finerenone (to block MR-driven direct fibrosis).
- Future Layers: Potential addition of ASIs (aldosterone production blockade) or ERAs (endothelin pathway interruption), creating "quadruple" or "quintuple" therapy.
The Phase 2 CONFIDENCE trial7, published in the New England Journal of Medicine in June 2025, demonstrated that simultaneous initiation of finerenone and an SGLT2 inhibitor (empagliflozin) achieved a 52% reduction in UACR (+29% vs finerenone alone, +32% vs empagliflozin alone), providing robust evidence for the effectiveness of the layered approach.
5. Translation to Preclinical Animal Models (A CRO Perspective)
These clinical paradigm shifts heavily influence how novel drug candidates must be tested in preclinical environments.
- UUO (Unilateral Ureteral Obstruction) Model: The gold standard for rapidly evaluating the transition from severe inflammation to aggressive tubulointerstitial fibrosis. It is ideal for screening the direct antifibrotic and anti-inflammatory mechanisms of drugs akin to Finerenone.
- Adenine-Induced CKD / Alport Syndrome Models: Models featuring progressive glomerulosclerosis and eGFR decline over weeks to months. These are critical for evaluating the long-term, functional renoprotective effects of SGLT2i and combination therapies.
- MASH/NASH Comorbid Models (e.g., GAN diet): Models that replicate the modern patient phenotype—featuring obesity, met-dysfunction, liver fibrosis, and diabetic nephropathy. These are becoming indispensable for evaluating the multi-organ protective effects of novel incretins (GLP-1/GIP/Glucagon multi-agonists).
6. Conclusion
In 2025, the frontier of CKD treatment has unequivocally shifted toward the strict control of "inflammation and fibrosis." Armed with Finerenone, SGLT2 inhibitors, and GLP-1RAs—three distinct but complementary weapons—and with ASIs, ERAs, and complement inhibitors rapidly advancing through clinical trials, long-term stabilization of renal function through multi-layered pharmacological intervention is becoming a widespread reality.
For developers of next-generation antifibrotic therapies, the critical challenge ahead will no longer be beating a placebo, but conclusively demonstrating a statistically significant add-on effect on top of this highly effective, multi-layered new standard of care.
References & Clinical Trial Information
Finerenone (nsMRA)
1. Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383:2219-2229. (FIDELIO-DKD: NCT02540993)
2. Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385:2252-2263. (FIGARO-DKD: NCT02545049)
3. FINE-ONE Trial. Finerenone in CKD Associated with Type 1 Diabetes. N Engl J Med. 2026. (NCT05901831)
SGLT2 Inhibitors
4. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446. (DAPA-CKD: NCT03036150)
5. The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388:117-127. (NCT03594110)
GLP-1 Receptor Agonists
6. Perkovic V, et al. Effects of Semaglutide on CKD Outcomes. N Engl J Med. 2024. (FLOW: NCT03819153)
Combination Therapy
7. Green JB, et al. Finerenone and Empagliflozin in Diabetic Kidney Disease. N Engl J Med. 2025. (CONFIDENCE: NCT05254002)
Aldosterone Synthase Inhibitors (ASIs)
8. Baxdrostat + Dapagliflozin Phase 3: NCT06268873
9. Lorundrostat Explore-CKD Phase 2: NCT06150924
10. Agarwal R, et al. BI 690517 in CKD. Lancet. 2024. Phase 3 EASi-KIDNEY: NCT06531824
Endothelin Receptor Antagonists (ERAs)
11. Atrasentan ALIGN Phase 3 (IgA Nephropathy): NCT04573478
12. Sparsentan — FDA Full Approval (2024) for IgA Nephropathy. Phase 3 DUPLEX (FSGS).
13. Zibotentan + Dapagliflozin ZENITH High Proteinuria Phase 3: NCT06087835
Complement Pathway Inhibitors
14. Iptacopan APPLAUSE-IgAN Phase 3: NCT04578834
15. Sibeprenlimab VISIONARY Phase 3: NCT05248646 — FDA Accelerated Approval (2025).